Table 2.

Univariate analysis of pathological features, PD-L1 expression and FOXP3⁺ Treginfiltration with OS and RFS in breast cancer patients

	OS			RFS
Variable	HR	95% CI	P	HR	95% CI	P
Age, years (<50 vs.≥50)	1.017	0.661-1.564	0.939	0.984	0.664-1.460	0.937
Tumor size, cm (≤2 vs. >2)	1.188	0.718-1.967	0.502	1.076	0.682-1.695	0.754
Histological Grade (I vs. II vs. III)	2.116	1.413-3.171	<0.001	2.075	1.437-2.997	<0.001
Lymph node stage(N0 vs. N1 vs. N2 vs. N3)	2.103	1.725-2.563	<0.001	2.045	1.709-2.446	<0.001
ER status (negative vs.positive)	0.389	0.251-0.600	<0.001	0.482	0.325-0.716	<0.001
PR status s(negative vs. positive)	0.437	0.279-0.684	<0.001	0.542	0.363-0.808	0.003
HER-2 status (negative vs. positive)	2.087	1.315-3.314	<0.001	1.753	1.135-2.709	0.011
PD-L1 (negative vs. positive)	2.544	1.607-4.028	<0.001	2.262	1.498-3.416	<0.001
FOXP3+ Tregs (low vs. high)	4.330	2.101-8.926	<0.001	2.418	1.400-4.178	0.002
Chemotherapy (No vs. Yes)	6.393	0.890-45.932	0.065	7.929	1.106-56.859	0.039
Radiotherapy (No vs. Yes)	2.596	1.474-4.572	0.001	2.649	1.608-4.364	<0.001
Endocrine therapy (No vs. Yes)	0.358	0.233-0.552	<0.001	0.470	0.314-0.703	<0.001

Lymph node stage: N0, indicates no lymph node metastasis; N1, 1-3 lymph node metastasis; N2, 4-9 lymph node metastasis; N3, ≥10 lymph node metastasis.

HR, hazard ratio; CI, confidence interval; OS: overall survival; RFS: recurrence-free survival.